ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER

21-22 February 2014
Amsterdam, The Netherlands

Chairs: C.H. Bangma, NL - J. Hugosson, SE
Co-Chair: L. Klotz, CA
Honorary Chair: L.J. Denis, BE
ESO Prostate Cancer Programme Coordinator: R. Valdagni, IT
Scientific Coordinators: M.J. Roobol, NL - S. Carlsson, SE/US
FOREWORD

Over the years, there has been increasing acceptance of active surveillance as an alternative to radical treatment for men with low risk prostate cancer. Unless the over-diagnosis of indolent prostate cancer is reduced by alternative diagnostic strategies, active surveillance will continue to play an important role. The challenge is to determine how new imaging methods and biomarkers can improve patient selection and how to incorporate drugs into active surveillance programmes.

ESO’s second Inside Track Conference “Active surveillance for Low Risk Prostate Cancer”, organized in collaboration with EAU and endorsed by Europa Uomo, aims at being an interactive educational activity in which attendees will enjoy presentations by internationally renowned researchers on active surveillance, who have helped develop and evaluate technologies that may change the selection and monitoring of patients.

Furthermore workshops will allow you to discuss a few selected hot topics with the top experts in that field. The remarks and conclusions of the workshops will give important insights into active surveillance practices applied in various countries.

When completing your registration form you will be asked to choose which workshop you would like to attend.

We would like to thank the European Association of Urology (EAU) and Europa Uomo for their participation and also, on behalf of the Scientific Coordinators, the Co-Chair, and the organizing team, we invite you to participate and contribute to a productive and enjoyable conference.

Chris Bangma
Chair

Jonas Hugosson
Chair

Riccardo Valdagni
ESO Prostate Cancer Programme Coordinator
FACULTY

C.H. Bangma
Department of Urology, Erasmus Medical Center, Rotterdam, NL

L. Bellardita
Prostate Cancer Programme, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

A. Briganti
Urological Institute, Ospedale San Raffaele, Milan, IT

S. Carlsson
Department of Surgery and Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, US and Sahlgrenska Academy at the University of Göteborg, SE

P.R. Carroll
Department of Urology, UCSF School of Medicine, San Francisco, US

L.J. Denis
Europa Uomo, Oncology Center Antwerp, BE

G. Feick
Europa Uomo, Antwerp, BE

J. Hugosson
Department of Urology, Sahlgrenska Academy at the University of Göteborg, SE

G. Jenster
Department of Urology, Erasmus Medical Center, Rotterdam, NL

Y. Kakehi
Department of Urology, Kagawa University Faculty of Medicine, Kagawa, JP

L.H. Klotz
Division of Urology, Sunnybrook Health Sciences Centre, Toronto, CA

I. Korfage
Division of Epidemiology, Department of Public Health, Erasmus Medical Center, Rotterdam, NL

A. Lane
School of Social and Community Medicine, University of Bristol, Bristol, UK

C. Moore
Division of Surgical and Interventional Science, University College London, London, UK

T. Pickles
Department of Radiation, British Cancer Agency, Vancouver, CA

H. Randsdorp
Europa Uomo, Antwerp, BE

A. Rannikko
Department of Urology, Helsinki University Hospital, Helsinki, FI

S. Roemeling
Department of Urology, University Medical Center, Groningen, NL

M.J. Roobol
Department of Urology, Erasmus University Medical Center, Rotterdam, NL

E. Steyerberg
Department of Public Health, Erasmus Medical Center, Rotterdam, NL

B.J. Trock
Department of Urology, Johns Hopkins School of Medicine, Baltimore, US

R. Valdagni
ESO Prostate Cancer Programme
Prostate Cancer Programme and Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT

R. Van den Bergh
Department of Urology, University Medical Centre, Utrecht, NL

H. Van der Poel
Department of Urology, Netherlands Cancer Institute, Amsterdam, NL

H. Van Poppel
Department of Urology, University Hospital of the KU, Leuven, BE

A. Villers
Department of Urology, Hôpital Huriez, Centre Hospitalier Regional Universitaire, Lille, FR

H. Wijkstra
Department of Urology, Academic Medical Center University Hospital, Amsterdam, NL
PROGRAMME

FRIDAY, 21 FEBRUARY

8:00  Registration
9:00  Welcome and objectives  C.H. Bangma, NL  J. Hugosson, SE
9:10  Prostate Cancer Programme - European School of Oncology  R. Valdagni, IT

OVER-DETECTION AND OVER-TREATMENT
Chairs: J. Hugosson, SE - B. Trock, US
9:20  Setting the stage: over-detection in cancer  J. Hugosson, SE
9:35  How to reduce the number needed to treat in prostate cancer screening  M.J. Roobol, NL

SELECTION AND MONITORING FOR ACTIVE SURVEILLANCE
9:50  Repeated biopsies: complications  A. Rannikko, FI
10:10 How accurately can MRI detect indolent disease?  A. Villers, FR
10:30  Coffee break
10:50  Triggers for reclassification in ongoing studies  L. Klotz, CA
11:10 The image based targeted biopsy: what are criteria of indolence?  C. Moore, UK
11:40  Contrast enhanced ultrasound. Toy or tool?  H. Wijkstra, NL
12:00  How to evaluate intermediate outcomes in men for active surveillance?  P. Carroll, US
12:20  Panel discussion: pitfalls and criticism of active surveillance  
  Chairs: P. Carroll, US - C. Moore, UK
  Questions and answers
12:50  Lunch and Poster Session
14:00  Best poster presentations
14:00  First poster
14:10  Second poster

APPLICATION OF EMERGING TECHNOLOGY AND BIOMARKERS FOR SCREENING, SURVEILLANCE AND TREATMENT
Chairs: T. Pickles, CA - A. Rannikko, FI
14:30  Biomarkers of indolent and aggressive prostate cancer - Application to active surveillance  B. Trock, US
14:50  Genomic and transcriptomic fingerprinting of prostate biopsies  G. Jenster, NL
15:10  Risk based prediction models for indolence: what is needed to incorporate new parameters?  E. Steyerberg, NL
15:30  Can MRI replace serial biopsies, and how to prove that?  C. Moore, UK
15:50  Panel discussion: Emerging technology and biomarkers: indolent or aggressive disease?  
  Chairs: T. Pickles, CA - A. Rannikko, FI
  Panelists: B. Trock, US - G. Jenster, NL - E. Steyerberg, NL - C. Moore, UK
  Questions and answers
16:15  Coffee break
16:30  Panel discussion: When to change current active surveillance protocols?  
  Chairs: C.H. Bangma, NL - J. Hugosson, SE
17:20  Posters viewing
SATURDAY, 22 FEBRUARY

EAU LECTURE
Chairs: H. Van Poppel, B - R. Valdagni, IT
8:00  Focal therapy vs active surveillance  H. Van der Poel, NL

THE QUALITY OF LIFE OF MEN ON ACTIVE SURVEILLANCE
Chairs: L. Bellardita IT - H. Randsdorp, BE - S. Roemeling, NL
8:45  Quality of life outcome in active surveillance PRIAS - The Netherlands  I. Korfage, NL
9:05  Living with untreated prostate cancer: predictors of poor quality of life - PRIAS Quality of Life Study at Milan National Cancer Institute  L. Bellardita, IT
9:25  Men’s experience of long term active surveillance - The PROTECT trial  A. Lane, UK
9:45  The patients’ perspective on active surveillance - The European Support  G. Feick, BE
10:00  Panel discussion: Discussion by all Consensus building
Chairs: C.H. Bangma, NL - J. Hugosson, SE
Questions and answers
10:30  Coffee break
10:45  Movember Lecture - “The global action programme dealing with active surveillance”  C.H. Bangma, NL
11:05  Simultaneous Workshops
Workshop #1
Patient selection for active surveillance based on indolent disease definitions
(S. Carlsson US/SE - E. Steyerberg, NL)
Workshop #2
Overview of the global active surveillance studies / ongoing protocols
(B. Trock, US - R. Van den Bergh, NL)
Workshop #3
Randomized clinical trials - How to incorporate agents into active surveillance programmes
(C.H. Bangma, NL - Y. Kakehi, JP)
Workshop #4
How to measure patient’s considerations and QoL in active surveillance programmes world wide
(L. Bellardita, IT - H. Randsdorp, BE)
Workshop #5
What studies need to be done to define indolence by emerging technology and biomarkers?
(C. Moore, UK - L. Klotz, CA)
13:00  Lunch
14:00  Reports from individual Working Groups and Discussion
Chair: P. Carroll, US - E. Steyerberg, NL
15:40  Discussion by all - Consensus building
16:30  Closing remarks  C.H. Bangma, NL  J. Hugosson, SE
Participants are invited to submit an abstract on research relating to the identification of potential indolent prostate cancer or on clinical studies relating to active surveillance of prostate cancer.

Abstracts will be considered for poster presentations only, except the two best abstracts posters which will be presented both as posters and as a 10-minute oral presentation on Friday, 21 February 2013. The two best abstracts will furthermore be awarded a prize of €200.

Ample opportunity will be given to the conference participants to view all posters. The Chair of the Poster Session will visit all posters and participants will be able to give a short oral explanation of the research described (no slides). The Poster Session is scheduled on day, time.

Accepted abstracts will be published in the event’s dedicated website.

**GUIDELINES**

- The abstracts should be limited to 2000 characters, including the title.
- The title should be in lower case letters
- Each author should be listed with First name, followed by Family Name
- The first author should be underlined (first author = corresponding author and presenter)
- List affiliation after the author’s list
- The full address with e-mail address, phone and fax number of the first author (+corresponding author and presenter) must be provided. The first author will receive an acknowledgment of receipt and all subsequent communication by e-mail
- For abstracts accepted for poster presentation and best abstract oral presentation, the first author will be the presenting author and is requested to register and participate in the Conference
- It is responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made

The acknowledgement of receipt of abstract will follow the submission. The abstract submission outcome will be notified by 13 December 2013 to the first author who will be required to register to the Conference (early registration deadline, 20 December 2013).
**GENERAL INFORMATION**

**ORGANISING SECRETARIAT**
Prostate Cancer Programme
European School of Oncology (ESO)
Via Turati 29 - 20121 Milan, Italy
Website: www.eso.net

**VENUE**
Beurs van Berlage
Damrak 243 - 1012 ZJ Amsterdam, NL
www.beursvanberlage.nl
Beurs van Berlage is in a 5 minutes walk from the Amsterdam railway station.

Programme, organisation and abstracts:
Rita De Martini (prostate@eso.net) - Tel:+39 02 85464527 - Fax: +39 02 85464545

Registrations:
Elena Fiore (efiore@eso.net) - Tel. + 39 02 85464529 - Fax: +39 02 85464545

Hotel Accommodation:
MCI Amsterdam’s Hotel Operations team at: aslrpc2014-hotels@mci-group.com
Tel: +31 (0)20 6793411 - Fax: +31 (0) 20 6737306

**ONLINE REGISTRATION**
Registration may be carried out online at www.eso.net or by returning the enclosed registration form

**REGISTRATION**
The registration fee includes participation in all sessions, coffee breaks and lunches, and a copy of the Programme booklet. Registration will be confirmed by e mail or by fax.

<table>
<thead>
<tr>
<th></th>
<th>Early (by 20 December 2013)</th>
<th>Late (by 20 January 2014)</th>
<th>On site (from 21 January 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration fee</td>
<td>EUR 250</td>
<td>EUR 350</td>
<td>EUR 450</td>
</tr>
<tr>
<td>Club ESO Members</td>
<td>EUR 200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESTRO Course Participants</td>
<td>EUR 200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EAU Members</td>
<td>EUR 200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trainees*</td>
<td>EUR 120</td>
<td>EUR 120</td>
<td></td>
</tr>
</tbody>
</table>

*(a supporting letter of Dept. Director is required)*

**CANCELLATION OF REGISTRATION OR REPLACEMENT**
Cancellations should be notified to ESO in writing by 20 January 2014. Replacement is allowed if written communication is received by 20 January 2014. In case of cancellation without replacement, the fee, less handling charges of EUR 100, will be refunded after the event.

**CME ACCREDITATION**
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the application can be obtained from the organising secretariat.

**HOTEL ACCOMMODATION**
If you require hotel accommodation in Amsterdam, please fill in the enclosed Hotel Accommodation Form and send it to MCI Amsterdam Hotel Reservations by e mail or by fax or book the hotel via ESO website at www.eso.net.

**Hotel booking conditions**
A full pre-payment by credit card, non refundable, is needed when booking. Availability is guaranteed until 20 January 2014. After that date, rooms will be provided upon request and based on availability.

**OFFICIAL LANGUAGE**
The official language of the Conference is English. No simultaneous translation will be provided.

**BADGE**
Your name badge is the only official evidence of registration and should be worn at all times during the Conference.

**INSURANCE**
The organisers bear no responsibility for untoward events in relation with the participation at the Conference. Participants are advised to take out their own personal and travel insurance coverage.
REGISTRATION FORM

ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER, 21-22 FEBRUARY 2014, Amsterdam, NL

Please fill in this form in BLOCK LETTERS and send by the deadline to:
European School of Oncology - Via Turati 29 - 20121 Milan - Italy - Fax: +39 02 85464545 - E mail: efiore@eso.net

ONLINE REGISTRATION IS AVAILABLE AT: WWW.ESO.NET

PARTICIPANT’S DETAILS
☐ Dr. ☐ Prof. ☐ Mrs. ☐ Mr.
Surname Name
Institute
Department
Street
Zip Code Town Country
Phone Fax Mobile
Email
Date of birth Birth date (town and country)
Profession
Specialisation Main field
VAT number (compulsory for self-employed persons)
Fiscal code (Italian residents only)

If your invoice details are different to those above, please complete the following section:

Invoice contact details
Address
Phone email
VAT number (compulsory for self-employed persons)
Fiscal Code (Italian residents only)

For organisation purposes, please select the workshop that you will attend:
☐ Workshop N.1 ☐ Workshop N.2 ☐ Workshop N.3 ☐ Workshop N.4 ☐ Workshop N.5

REGISTRATION FEES:
Early (by 20 December 2013) Late (by 20 January 2014)
Registration fee ☐ EUR 250 ☐ EUR 350
Club ESO Members ☐ EUR 200 ☐ EUR 350
ESTRO Course Participants ☐ EUR 200 ☐ EUR 350
EAU Members ☐ EUR 200 ☐ EUR 350
Trainees* ☐ EUR 120 ☐ EUR 120

* (a supporting letter of Dept. Director is required)

PAYMENT DETAILS:
The registration is processed when payment accompanies the form (credit card details or copy of bank transfer)

☐ Visa/Mastercard Card Number / / / / /
Expire date / / CV2 code

☐ BANK TRANSFER with no cost to the beneficiary (please provide a copy of the bank transfer):
Bank:
Account holder:
Number:
IBAN:
Reference: “Active Surveillance Conference 2014” + your name

I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature Date
MCI Amsterdam, the official housing partner for “Active Surveillance for Low Risk Prostate Cancer”, has reserved a number of hotel rooms in three hotels in different price categories. These hotels are located in the city centre of Amsterdam, and the Beurs van Berlage (meeting venue) can easily be reached from all hotels.

## Hotel Accommodation

<table>
<thead>
<tr>
<th>Hotel name</th>
<th>Colour in map</th>
<th>Category</th>
<th>Room rate</th>
<th>Distance to the venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ibis Amsterdam Centre</td>
<td>blue</td>
<td>3</td>
<td>€109</td>
<td>8 min walking</td>
</tr>
<tr>
<td>Mercure Amsterdam Arthur Frommer</td>
<td>red</td>
<td>4</td>
<td>€129</td>
<td>20 min walking or 10 min by public transportation</td>
</tr>
<tr>
<td>MGallery The Convent Amsterdam</td>
<td>green</td>
<td>4</td>
<td>€144</td>
<td>5 min walking</td>
</tr>
</tbody>
</table>

**Venue: Beurs van Berlage**

Above rates are based on single occupancy, include breakfast and exclude 5.5% city tax.

### Ibis Amsterdam Centre
Ibis Amsterdam Centre is situated by the main train station. Trains, metros, buses, trams and taxis all drop you right to the door. Schiphol airport is just 15 minutes away by train, the Beurs van Berlage less than 10 minutes walking. The hotel offers 363 rooms, including 3 for disabled guests.

### Mercure Amsterdam Arthur Frommer
The charming Hotel Mercure Amsterdam Arthur Frommer was refurbished in 2008. It is situated on a quiet street in the heart of Amsterdam, within walking distance of numerous shops, restaurants, museums and visitor attractions. The hotel has tastefully designed rooms and bathrooms, a bar, a breakfast room and a limited number of private parking spaces available (at a surcharge).

### MGallery The Convent Amsterdam
The Convent Hotel Amsterdam is a 4-star hotel with a unique history that makes it the perfect place to stay. Its location in the centre of Amsterdam is ideal for visiting the city. It is a five-minute walk from Central Station, Dam Square and the Royal Palace. The hotel building previously housed 2 monasteries from the 13th & 14th centuries, plus a printing house.

### Hotel Booking Conditions
A full prepayment by credit card, non-refundable, is needed when booking online. Availability is guaranteed until 20 January 2014. After that date, rooms will be provided upon request and based on availability.

Should you have any questions regarding hotel accommodation, please do not hesitate to contact MCI Amsterdam’s Hotel Operations team at: aslpc2014-hotels@mci-group.com

**Hotel Reservations team:**
MCI-Eurocongress vof - Jan van Goyenkade 11 - 1075 HP Amsterdam
Tel.: +31 (0)20 6793411 - Fax: +31 (0)20 6737306 - E-mail: aslpc2014-hotels@mci-group.com
### HOTEL ACCOMMODATION FORM

**ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER**  
21-22 FEBRUARY 2014, Amsterdam, The Netherlands

Please complete this form using **CAPITAL** letters and send to **Hotel Reservations at MCI Amsterdam**  
Fax: +31 (0)20 673 7306 - E-mail: asrlpc2014-hotels@mci-group.com

For online accommodation bookings and more information on the hotels, please go to [www.eso.net](http://www.eso.net)

### PARTICIPANT’S INFORMATION

<table>
<thead>
<tr>
<th>Surname</th>
<th>First Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>Postcode/Zipcode</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State/County</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tel (including country code)</th>
<th>Fax (including country code)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### RESERVATION

All rates quoted are based on single occupancy, including breakfast and excluding 5,5% city tax

- **Ibis Amsterdam Centre (****)**  
  € 109 per room per night [ ]

- **Mercure Amsterdam Arthur Frommer (*****)**  
  € 129 per room per night [ ]

- **Mgallery The Convent Amsterdam (****)**  
  € 144 per room per night [ ]

<table>
<thead>
<tr>
<th>Check in date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Check out date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sharing with (only if double occupancy)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

Please indicate any special requests

### TERMS AND CONDITIONS

Full pre-payment required at the time of booking. Please note it is not possible to cancel or modify the booking once you have received the confirmation of your reservation.

### CREDIT CARD DETAILS

Accommodation payment needs to be done at the time of reservation and extras will be paid directly to the hotel. Please provide your credit card details (Mastercard or Visa Card only); without credit card details it will not be possible to make a reservation.

<table>
<thead>
<tr>
<th>CREDIT CARD</th>
<th>Mastercard</th>
<th>Visa Card</th>
</tr>
</thead>
<tbody>
<tr>
<td>Credit Card number</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Card holder’s name (in Capital letters)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Card holder’s signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CVV number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

I agree to the terms and conditions and that my credit card details will be used for payment and confirming the reservation.

Signature

If you require any assistance with your booking please do not hesitate to contact the Hotel Reservations team at: Tel.: +31 (0)20 679 3411 - E-mail: asrlpc2014-hotels@mci-group.com